Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 62.59% is in line with its 4-year average of 59.30%, near the high end of its 4-year range (-88.20%–86.47%).
268.31% above its 12-month average of 16.99%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): -88.20%.
GROSS MARGIN
62.59%
GROSS MARGIN AVG TTM
16.99%
GROSS MARGIN AVG 3Y
52.99%
GROSS MARGIN AVG 5Y
N/A
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+268.31%
CURRENT VS 3Y AVG
+18.11%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.82%
median of 845 covered companies
CURRENT VS SECTOR MEDIAN
+53.33%
vs the sector median at left
iTonic Holdings Ltd.
Market Cap
$25.45M
Gross Margin
62.59%
TTM Avg
16.99%
3Y Avg
52.99%
5Y Avg
N/A
Market Cap
$24.94M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$24.18M
Gross Margin
0.00%
TTM Avg
49.92%
3Y Avg
18.04%
5Y Avg
44.48%
Market Cap
$27.21M
Gross Margin
-423.83%
TTM Avg
-211.91%
3Y Avg
-105.96%
5Y Avg
-82.75%
Market Cap
$23.26M
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
99.50%
5Y Avg
86.48%
Market Cap
$27.69M
Gross Margin
-717.37%
TTM Avg
-308.69%
3Y Avg
-108.42%
5Y Avg
-83.18%
Market Cap
$22.88M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| iTonic Holdings Ltd. (ITOC) | $25.45M | 62.59% | 16.99% | 52.99% | N/A |
| InspireMD, Inc. (NSPR)vs › | $25.29M | 29.50% | 25.49% | 25.43% | 20.30% |
| Atossa Therapeutics, Inc. (ATOS)vs › | $24.94M | 0.00% | 0.00% | 0.00% | 0.00% |
| ABVC BioPharma, Inc. (ABVC)vs › | $24.18M | 0.00% | 49.92% | 18.04% | 44.48% |
| Kyntra Bio, Inc. (KYNB)vs › | $23.92M | 91.37% | 69.42% | 78.99% | 53.34% |
| Seres Therapeutics, Inc. (MCRB)vs › | $27.21M | -423.83% | -211.91% | -105.96% | -82.75% |
| TherapeuticsMD, Inc. (TXMD)vs › | $23.26M | 100.00% | 100.00% | 99.50% | 86.48% |
| aTyr Pharma, Inc. (ATYR)vs › | $27.69M | -717.37% | -308.69% | -108.42% | -83.18% |
| Rein Therapeutics Inc. (RNTX)vs › | $22.88M | 0.00% | 0.00% | 0.00% | 0.00% |
| LeonaBio, Inc. (LONA)vs › | $22.54M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
62.6%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | -88.20% |
| 2025-12-31 | 60.15% |
| 2025-06-30 | 79.03% |
| 2024-12-31 | 83.95% |
| 2024-06-30 | 86.28% |
| 2023-12-31 | 75.11% |
| 2023-06-30 | 74.62% |
| 2022-12-31 | 76.33% |
| 2022-06-30 | 86.47% |
